Cqs Cayman Lp adds Ariad Pharmaceuticals (ARIA) to its portfolio

Ariad Pharmaceuticals (ARIA) : Cqs Cayman Lp added new position in Ariad Pharmaceuticals during the most recent quarter end. The investment management firm now holds 1,132,000 shares of Ariad Pharmaceuticals which is valued at $11,342,640 , the company said in a statement filed on Aug 9, 2016 with the SEC.Ariad Pharmaceuticals makes up approximately 2.63% of Cqs Cayman Lp’s portfolio.

Other Hedge Funds, Including , Acrospire Investment Management added ARIA to its portfolio by purchasing 1,825 company shares during the most recent quarter which is valued at $18,287. Ariad Pharmaceuticals makes up approx 0.01% of Acrospire Investment Management’s portfolio. Gsa Capital Partners Llp sold out all of its stake in ARIA during the most recent quarter. The investment firm sold 12,099 shares of ARIA which is valued $122,926.California Public Employees Retirement System reduced its stake in ARIA by selling 11,000 shares or 3.02% in the most recent quarter. The Hedge Fund company now holds 352,900 shares of ARIA which is valued at $3,504,297. Ariad Pharmaceuticals makes up approx 0.01% of California Public Employees Retirement System’s portfolio. Smith Asset Management Group Lp added ARIA to its portfolio by purchasing 36,250 company shares during the most recent quarter which is valued at $305,225. Ariad Pharmaceuticals makes up approx 0.01% of Smith Asset Management Group Lp’s portfolio.Msi Financial Services Inc reduced its stake in ARIA by selling 62 shares or 1.2% in the most recent quarter. The Hedge Fund company now holds 5,103 shares of ARIA which is valued at $42,967.

Ariad Pharmaceuticals closed down -0.1 points or -0.95% at $10.45 with 29,40,173 shares getting traded on Wednesday. Post opening the session at $10.55, the shares hit an intraday low of $10.34 and an intraday high of $10.55 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

On the company’s financial health, Ariad Pharmaceuticals reported $0.59 EPS for the quarter, beating the analyst consensus estimate by $ 0.70 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $-0.11. The company had revenue of $68.13 million for the quarter, compared to analysts expectations of $62.11 million. The company’s revenue was up 133.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.28 EPS.

ARIAD Pharmaceuticals Inc. is a global oncology company. The Company is engaged in the discovery development and commercialization of small molecule drug indicated for the treatment of cancer. The Company’s product pipeline includes Iclusig (ponatinib) brigatinib (AP26113) AP32788 and ridaforolimus. Iclusig is a tyrosine kinase inhibitor (TKI) which is approved in the United States Europe and Australia for the treatment of adult patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). AP32788 is an orally active TKI. Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).

Leave a Reply

Ariad Pharmaceuticals - Is it time to Sell?

Top Brokerage Firms are advising their investors on Ariad Pharmaceuticals. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.